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Abstract
The polypeptide ubiquitin is used in many processes as different as endocytosis, multivesicular body
formation, and regulation of gene transcription. Conjugation of a single ubiquitin moiety is typically
used in these processes. A polymer of ubiquitin moieties is required for tagging proteins for
proteasomal degradation. Besides its role in protein degradation, ubiquitin is also engaged as mono-
or polymer in intracellular signalling and DNA repair. Since free ubiquitin is present in limiting
amounts in cells, changes in the demands for ubiquitin in any of these processes is likely to indirectly
affect other ubiquitin modifications. For example, proteotoxic stress strongly increases poly-
ubiquitylated proteins at the cost of mono-ubiquitylated histones resulting in chromatin
remodelling and altered transcription. Here we discuss the interconnection between ubiquitin-
dependent processes and speculate on the functional significance of the ubiquitin equilibrium as a
signalling route translating cellular stress into molecular responses.
Background
Ubiquitin is a small polypeptide (76 amino acids) used in
many essential cellular processes. Ubiquitin is abundantly
expressed in eukaryotes and can be found in all cell types
and tissues with up to 108 copies per cell [1]. Processes as
different as endocytosis, signal transduction, DNA repair,
transcription and chromatin remodelling require ubiqui-
tin for proper functioning (reviewed in [2-6]; Figure 1).
Biochemical studies suggest that a polymer of four or
more ubiquitin moieties is required to label protein sub-
strates for recognition by proteasomes [7,8]. Ubiquitin is
post-translational conjugated to protein substrates
through an isopeptide bond between the C-terminal gly-
cine residue of ubiquitin and the ε-amino group of a
lysine residue or sometimes the α-amino group of a target
protein. The conjugated ubiquitin can be a substrate for
further ubiquitylation through one of its seven lysine res-
idues leading to the formation of a poly-ubiquitin chain.
Single ubiquitin and poly-ubiquitin conjugates can be rec-
ognized by various proteins containing ubiquitin binding
domains (UBDs). These UBDs act similar as, for example,
SH2 and SH3 domains that bind their targets dependent
on phosphorylation of specific target residues. These post-
translational modifications are a general mechanism for
regulating protein interactions [9]. A large number of dif-
ferent UBDs have been identified in unrelated proteins
underscoring the complexity and versatility of ubiquitin
modifications and ubiquitin-dependent interactions.
Ubiquitin contains seven lysine residues, all of which can
be used to form poly-ubiquitin chains [10]. Poly-ubiqui-
tin chains linked through lysine-48 are most common
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and usually target substrate proteins for proteolysis. Other
ubiquitin modifications, like poly-ubiquitylation through
lysine-6 and lysine-63 are used for processes like DNA
repair, endocytosis, and ribosomal protein synthesis [11-
15]. Mono-ubiquitylation is involved in endocytosis,
multivesicular body formation and chromatin remodel-
ling [16]. As a major constituent of chromatin, histones
are subjected to several post-translational modifications
including ubiquitylation [17,18]. Ubiquitylation of his-
tones affect transcriptional activity and chromatin remod-
elling [4,19] and has recently been reported to be involved
in DNA repair mechanisms as well [20-22].
A cascade of different classes of enzymes is required for
identification and ubiquitylation of proteins (reviewed in
[23,24]). The first step in ubiquitylation is performed by
the E1 ubiquitin-activating enzyme, which activates ubiq-
uitin by formation of a thiol-ester bond between a
cysteine residue of E1 and the carboxyl terminus of ubiq-
uitin [25]. The activated ubiquitin molecule is subse-
quently passed on to one of the different E2 ubiquitin
conjugating enzymes, which also establishes a thiol-ester
linkage with ubiquitin. Substrate proteins are recognized
by a specific E3 ubiquitin ligase, which, in combination
with E2 enzymes, ubiquitylate the substrate [26]. Combi-
nations of about twenty human E2 conjugating enzymes
with several hundreds of distinct E3 ubiquitin ligases
enlarge the variety and specificity in recognizing and ubiq-
uitylating target proteins. Similar to most post-transla-
tional signalling modifications, ubiquitin modifications
are dynamic. Ubiquitin can be removed from substrates
by a heterogeneous family of specific deubiquitylation
enzymes (DUBs) [27]. DUBs are proteases that catalyze
the cleavage between the C-terminal glycine-76 of ubiqui-
Ubiquitin: forms and functions Figure 1
Ubiquitin: forms and functions. Free ubiquitin molecules are present in both the nucleus and the cytosol; the protein is 
small enough for passive diffusion through the nuclear pore between the two compartments. Ubiquitin conjugation to target 
proteins plays a central role in many processes of the cell. The best-known function of ubiquitin is its involvement in protein 
degradation via poly-ubiquitylation in the nucleus and cytoplasm. Mono-ubiquitylation of proteins has various functions depend-
ing on the target protein; it can vary from involvement in endocytosis at the plasma membrane, to DNA repair in the nucleus.Cell Division 2006, 1:21 http://www.celldiv.com/content/1/1/21
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tin and the substrate. DUBs may thus counteract specific
processes by removing mono-ubiquitin or poly-ubiquitin
from various substrates like histones, proteasome sub-
strates and other proteins. For example, the 19S lid of the
proteasome contains a DUB (Rpn11) for the removal of
poly-ubiquitin from proteasome substrates prior to prote-
olysis [28,29]. In addition to deubiquitylation activities,
DUBs are involved in processing newly synthesized, inac-
tive ubiquitin precursors. Thus DUBs generate all free
ubiquitin molecules, and are essential for the progression
of the ubiquitin cycle and the (re)generation of non-con-
jugated, free ubiquitin, which can be used for new ubiq-
uitylation reactions. Here we discuss the ubiquitin
homeostasis and its link to various cellular processes.
Different pools of ubiquitin
Several groups have described the existence of various
forms of ubiquitin in eukaryotic cells, including free ubiq-
uitin molecules, mono- and poly-ubiquitylated proteins
[30-34]. These pools are not static and ubiquitin cycles
dynamically between these pools mediated by ubiquityla-
tion and deubiquitylation enzymes [35,36]. The dynam-
ics of the different ubiquitin pools could be visualized in
living cells using a GFP-ubiquitin (GFP-Ub) fusion con-
struct [37]. Although this construct is about 4-fold larger
than unmodified ubiquitin, it still reflected in many
aspects the behaviour and localization of the endogenous
protein in mono-ubiquitin modification and use in poly-
ubiquitin chains for degradation [37,38]. The majority of
ubiquitin is present in (large) conjugates while only a
small fraction is free. A major pool of ubiquitin is conju-
gated to histone 2A and 2B under normal circumstances
[4,37].
To monitor the amount of free ubiquitin in living cells the
nuclear pore was used as a molecular sieve in a FLIP (Flu-
orescence Loss In Photobleaching) protocol wherein the
GFP fluorescence in either the complete nucleus or cyto-
plasm was bleached and the effect of GFP-Ub fluorescence
in the other compartment was measured. The rationale
behind this approach is that proteins up to approximately
50 kDa can passively diffuse through the nuclear pore,
whereas larger species (like conjugated ubiquitin) are
excluded [39]. The FLIP experiment revealed different
pools of GFP-Ub in the cytosol as well as the nucleus. A
small fraction of GFP-Ub rapidly diffused from the non-
bleached into the bleached compartment, representing
the free pool of unconjugated GFP-Ub. Slowly other GFP-
Ub entered the bleached compartment that may have
resulted from generation of free GFP-Ub by release from
substrate proteins like histones and proteasome substrates
by DUBs. Similar results were obtained with a photoacti-
vatable form of GFP-Ub where a region in the nucleus was
activated and fluorescence accumulated slowly in the
cytoplasm in time. These observations indicate that dur-
ing physiological conditions only a small portion of ubiq-
uitin is in the monomeric form. Using these approaches,
three distinct ubiquitin pools could be distinguished in
the cell: a small fraction of free monomeric ubiquitin; a
major fraction of ubiquitylated proteins and mono-ubiq-
uitylated histones. Smaller amounts of ubiquitin are used
for processes like endocytosis and multivesicular body
formation and therefore not easily detected by live cell
imaging where only the major fractions of ubiquitin are
distinguishable.
Ubiquitin homeostasis
Given the availability of a small pool of free ubiquitin,
free ubiquitin has to be replenished continuously by
DUBs. This ubiquitin cycle is essential to supply ubiquitin
to substrates in a multitude of nuclear and cytosolic proc-
esses (Figure 2). But what happens when the ubiquitin
equilibrium is disturbed? Inhibition of the proteasome
results in accumulation of poly-ubiquitylated proteins.
This is a reflection of proteotoxic stress since identical
effects on poly-ubiquitin were observed following cell
exposure to thermal stress conditions. Under these condi-
tions, heat-labile proteins denature and provide the cell
with an overload of proteasomal substrates. After a heat
shock, the quantity of poly-ubiquitylated proteins
increased dramatically. Since free ubiquitin is present in
only in limiting amounts and neo-synthesis cannot com-
pensate the acute needs for ubiquitin, this implies that
ubiquitin molecules have to come from other sources to
accommodate the increase in poly-ubiquitylated species.
Accordingly several studies have shown that, following
proteotoxic stress by proteasome inhibition, a redistribu-
tion of ubiquitin from the nucleus to the cytosol was
observed in parallel with deubiquitylation of histones
[37,40,41].
In principle, histone deubiquitylation could be the result
of enhanced deubiquitylation activity following proteo-
toxic stress. This was assayed using photo-activated GFP-
Ub in a protocol where the fate (i.e. the off-rate) of ubiq-
uitin fluorescence was followed in one half of the nucleus.
Proteotoxic stress did not affect the off-rate of fluorescent
(photoactivated) GFP-Ub from histones indicating the
DUBs were not activated by proteotoxic stress [37]. Anti-
body microinjection experiments supported the idea that
histone deubiquitylation was the result of an altered equi-
librium in the ubiquitin cycle [37]. Proteotoxic stress
results in an increased requirement for free ubiquitin for
incorporation in poly-ubiquitylated substrates at the cost
of mono-ubiquitylated histones. We speculate that
through the limited pool of ubiquitin enhanced poly-
ubiquitylation following proteotoxic stress is sensed by
the nucleus by affecting the histone-ubiquitin status and
thus the transcriptome.Cell Division 2006, 1:21 http://www.celldiv.com/content/1/1/21
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Coupling cellular processes by the ubiquitin 
cycle
Ubiquitylation of histones is one of the major (and larg-
est) modifications in chromatin. This modification is in
mammalian cells mainly found on the core histone H2A.
Approximately 5–15% of histone H2A is ubiquitylated,
and this is associated with condensed DNA and gene
silencing [42-44]. H2B ubiquitylation is essential for the
sliding activity of RNA polymerase II and regulates tran-
scription [45]. Deubiquitylation of histones during prote-
otoxic stress conditions could have serious consequences
for gene transcription/silencing and chromatin arrange-
ment. Effects on transcription (via ubiquitylated histones)
are thus a predicted response to proteotoxic-mediated
effects on the ubiquitin cycle [40,41]. In addition, ubiq-
uitylation of histones is involved in the regulation of
other post-transcriptional histone modifications like
acetylation and methylation [4]. Although histone ubiq-
uitylation is a prerequisite for these modifications, they
do not follow the same kinetics. Ubiquitin modified his-
tones turn over every 2–3 hours [37] whereas acetylation
and methylation modifications are much more stable
[17,46]. Changes in the ubiquitin equilibrium are
expected to influence these modifications translating in
effects on transcription regulation and chromatin remod-
elling. These findings may point towards a ubiquitin-
dependent regulation mechanism based on a delicate
ubiquitin homeostasis. Consequently, different cellular
processes can influence each other through the availabil-
ity of the rate-limiting pool of free ubiquitin. This limited
pool of free ubiquitin can be of functional significance to
couple proteasomal activity to chromatin remodelling
and in fact act as a novel signal transduction pathway,
going from stress to signalling to the nucleus by affecting
ubiquitin-histone modifications. Histone ubiquitylation
is also important for other processes like DNA replication,
repair and recombination. Often specific histones (like
H2A, H3 and H4 for nucleotide excision repair) are tar-
geted by ubiquitylation [20-22]. The key factor in the
ubiquitin cycle is the existence of a limited pool of free
ubiquitin, which couples the use of ubiquitin for poly-
ubiquitin to (swift) effects on histone ubiquitylation. As a
result, transcription, DNA repair and replication may all
be affected by proteotoxic stress conditions.
Conclusion and relevance
Regulated protein turnover by the ubiquitin-proteasome
system (UPS) is essential for the survival of eukaryotic
cells. This process is required for various cellular processes
such as cell cycle control, signalling pathways, transcrip-
tion and protein quality control. Alterations in the UPS
are correlated with a variety of human pathologies, like
cancer, immunological disorders, inflammation and neu-
rodegenerative diseases [47]. The exact role of the UPS in
the pathophysiology of these diseases however, remains
poorly understood. Numerous studies suggest that inhibi-
tion of the proteasome may be efficient in the treatment
in cancer and inflammation (reviewed in [48,49]). It is
well established that many cancer cells are sensitive to
proteasomal inhibitors, which often induce growth arrest
and killing. Proteasome inhibitors will prevent the degra-
dation of the regulator proteins resulting in cell cycle
arrest and apoptosis. However, a disturbed ubiquitin
homeostasis may contribute to cell death in proteasome
The ubiquitin cycle Figure 2
The ubiquitin cycle. Free ubiquitin plays a central role in the biochemistry of the cell; all processes that consume ubiquitin 
ultimately have to derive it from freely available ubiquitin. Because the amount of free ubiquitin is relatively small, processes 
that consume large amounts of ubiquitin will indirectly influence other cellular processes that depend on ubiquitin.Cell Division 2006, 1:21 http://www.celldiv.com/content/1/1/21
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inhibitor-treated cells as well. The pool of free ubiquitin
can be depleted through capture in poly-ubiquitylated
proteasomal substrates so that other ubiquitin-dependent
processes are negatively affected. In addition, histone deu-
biquitylation may suffice to induce growth arrest.
Many neurological disorders such as Alzheimer's disease,
Parkinson's disease, and Huntington's disease are caused
by an accumulation of aberrant proteins leading to the
formation of protein aggregates, inclusions and plaques.
It is not completely clear why the UPS is failing to clear
these aberrant proteins. For polyglutamine diseases like
Huntington's disease it has been demonstrated that the
UPS is unable to clear inclusions [50-52], and that protea-
somes cannot degrade aggregated polyglutamine proteins
[53] and polyglutamine peptides [54]. In some disorders,
mutations in proteins of the UPS are implicated [55]. In
addition to the accumulation of aberrant proteins many
other abnormalities such as impaired axonal transport
[56,57] and altered transcription regulation [58-61] are
associated with these diseases (reviewed in [62]).
Although these alterations in axonal transport and tran-
scription regulation can be explained by interference of
mutations in disease-related proteins, the pathogenic
mechanisms leading to neuronal death and the involve-
ment of protein aggregates are still largely unknown.
Intriguingly, the processes that are affected in these disor-
ders have at least one factor in common; they all require
ubiquitin. In a number of disorders the accumulated pro-
teins are ubiquitylated, while protein aggregates are also
enriched in proteasomes. The question arises whether the
sensitive ubiquitin equilibrium in these disorders is dis-
turbed as a consequence of capture of poly-ubiquitylated
proteins and/or inactive proteasomes in aggregates. A dis-
turbed ubiquitin homeostasis might also contribute to
alterations in, at first glance, unrelated cellular processes
in neurological disorders. It is tempting to speculate that
accumulation of aberrant proteins in these disorders dis-
rupts the sensitive ubiquitin equilibrium, by trapping a
significant fraction of ubiquitin and/or rendering proteas-
omes inactive in inclusion bodies and aggregates. As a
consequence other processes requiring the availability of
ubiquitin may be negatively influenced.
The flux of free ubiquitin between different cellular proc-
esses could be a passive mechanism in which unconju-
gated ubiquitin diffuses intracellular until it is utilized in
ubiquitylation processes. However, a recent publication
suggest that active factors could actually be involved in
channelling ubiquitin from one ubiquitin-dependent
process to another with temporally a higher priority [63].
It has been proposed that the DUB Doa1 helps to control
DNA damage responses by releasing ubiquitin from pro-
teasomal degradation into mechanisms involved in chro-
matin remodelling and DNA repair [63].
Ubiquitin seems more then just a signalling molecule
involved in the regulation of various distinct processes in
eukaryotic cells. The dynamic behaviour of ubiquitin
modifications creates an equilibrium which allows cross-
talk between different cellular processes that may allow
cells to translate cellular stress to molecular responses by
affecting the transcriptome.
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